Iovance Biotherapeutics, Inc. (0JDK.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 07:02PM BST
| Previous close | 10.41 |
| Open | 10.47 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 10.23 - 10.60 |
| 52-week range | 3.22 - 18.31 |
| Volume | |
| Avg. volume | 53,275 |
| Market cap | 13.872M |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Iovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ...
First Quarter Financials Reflect Strategic Expansion and Market Penetration
- Insider Monkey
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript May 9, 2024 Iovance Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Iovance Biotherapeutics Conference Call to discuss the First Quarter 2024 Results and recent Corporate […]
- Zacks
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.
© 2024 Yahoo. All rights reserved.